Section one: Contracting authority
one.1) Name and addresses
NHS England
Wellington House, 133-135 Waterloo Rd
London
SE1 8UG
Contact
Jessica Gaucher-Thompson
jessica.gaucher-thompson@nhs.net
Country
United Kingdom
Region code
UKJ1 - Berkshire, Buckinghamshire and Oxfordshire
Internet address(es)
Main address
Buyer's address
one.4) Type of the contracting authority
Body governed by public law
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Tumour Infiltrating Lymphocyte(TIL) Therapy Hubs for Melanoma(Adults)
two.1.2) Main CPV code
- 85100000 - Health services
two.1.3) Type of contract
Services
two.1.4) Short description
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).
Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752
The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.
The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West
This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.
As a result of this procurement exercise the commissioner intends to award 12 separate contracts across the 7 Lots.
The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
two.1.6) Information about lots
This contract is divided into lots: Yes
two.1.7) Total value of the procurement (excluding VAT)
Value excluding VAT: £142,512,000
two.2) Description
two.2.1) Title
Lot 1 - London
Lot No
1
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKI - London
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).
Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752
The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.
The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West
This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.
As a result of this procurement exercise, the Commissioner intends to award four separate contracts under Lot 1 - London.
The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.
The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
two.2.5) Award criteria
Quality criterion - Name: Quality & innovation / Weighting: 50
Quality criterion - Name: Value / Weighting: 2
Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21
Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17
Quality criterion - Name: Social Value / Weighting: 10
Cost criterion - Name: Not Applicable / Weighting: 0
two.2.11) Information about options
Options: Yes
Description of options
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 2 - East of England
Lot No
2
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKH - East of England
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).
Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752
The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.
The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West
This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.
As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 2 - East of England.
The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.
The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
two.2.5) Award criteria
Quality criterion - Name: Quality & innovation / Weighting: 50
Quality criterion - Name: Value / Weighting: 2
Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21
Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17
Quality criterion - Name: Social Value / Weighting: 10
Cost criterion - Name: Not Applicable / Weighting: 0
two.2.11) Information about options
Options: Yes
Description of options
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 3: South East
Lot No
3
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKJ - South East (England)
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).
Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752
The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.
The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West
This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.
As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 3 - South East.
The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.
The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
two.2.5) Award criteria
Quality criterion - Name: Quality & innovation / Weighting: 50
Quality criterion - Name: Value / Weighting: 2
Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21
Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17
Quality criterion - Name: Social Value / Weighting: 10
Cost criterion - Name: Not Applicable / Weighting: 0
two.2.11) Information about options
Options: Yes
Description of options
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 4: South West
Lot No
4
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKK - South West (England)
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).
Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752
The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.
The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West
This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.
As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 4 - South West.
The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.
The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
two.2.5) Award criteria
Quality criterion - Name: Quality & innovation / Weighting: 50
Quality criterion - Name: Value / Weighting: 2
Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21
Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17
Quality criterion - Name: Social Value / Weighting: 10
Cost criterion - Name: Not Applicable / Weighting: 0
two.2.11) Information about options
Options: Yes
Description of options
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 5: Midlands
Lot No
5
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKF - East Midlands (England)
- UKG - West Midlands (England)
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).
Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752
The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.
The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West
This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.
As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 5 - Midlands.
The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.
The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
two.2.5) Award criteria
Quality criterion - Name: Quality & innovation / Weighting: 50
Quality criterion - Name: Value / Weighting: 2
Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21
Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17
Quality criterion - Name: Social Value / Weighting: 10
Cost criterion - Name: Not Applicable / Weighting: 0
two.2.11) Information about options
Options: Yes
Description of options
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 6: North East & Yorkshire
Lot No
6
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKC - North East (England)
- UKE - Yorkshire and the Humber
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).
Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752
The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.
The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West
This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.
As a result of this procurement exercise, the Commissioner intends to award a contract under Lot 6 - North East and Yorkshire.
The approximate lifetime value of the contract is £11,876,000, subject to the number of patients treated.
The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
two.2.5) Award criteria
Quality criterion - Name: Quality & innovation / Weighting: 50
Quality criterion - Name: Value / Weighting: 2
Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21
Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17
Quality criterion - Name: Social Value / Weighting: 10
Cost criterion - Name: Not Applicable / Weighting: 0
two.2.11) Information about options
Options: Yes
Description of options
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Lot 7: North West
Lot No
7
two.2.2) Additional CPV code(s)
- 85100000 - Health services
two.2.3) Place of performance
NUTS codes
- UKD - North West (England)
two.2.4) Description of the procurement
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England (referred to as the Commissioner), invited suitably qualified and experienced providers to respond to a Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).
Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a trust with immediate access to an Intensive Therapy
Unit (ITU).
Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date in 2026 in line with NICE guidance: https://www.nice.org.uk/guidance/indevelopment/gid-ta10752
The treatment is complex to administer, requiring surgical expertise for tumour
resection, melanoma expertise for patient selection and management post-treatment and cell therapy expertise to administer the cell therapy and manage the side effects and associated care of both Lifileucel and IL-2 administration.
The key objective of the Procurement was to commission Tumour Infiltrating Lymphocyte (TIL)Therapy Hubs for adult patients across the following seven (7) geographical regions to serve the population of England:
Lot 1: London
Lot 2: East of England
Lot 3: South East
Lot 4: South West
Lot 5: Midlands
Lot 6: North East and Yorkshire
Lot 7: North West
This process was designed to enable any provider meeting the required standards to be awarded a contract, with no restriction on the number of sites commissioned.
As a result of this procurement exercise, the Commissioner intends to award two separate contracts under Lot 7 - North West.
The approximate lifetime value of each contract is £11,876,000, subject to the number of patients treated.
The service is due to commence on 1st May 2025, subject to NICE guidance, for a period of 5 years with the Commissioners having the option to extend for up to an additional 4 year(s)(maximum contract duration 9 years).
two.2.5) Award criteria
Quality criterion - Name: Quality & innovation / Weighting: 50
Quality criterion - Name: Value / Weighting: 2
Quality criterion - Name: Integration, Collaboration & Service Sustainability / Weighting: 21
Quality criterion - Name: Improving Access, Reducing Health Inequalities and Facilitating Choice / Weighting: 17
Quality criterion - Name: Social Value / Weighting: 10
Cost criterion - Name: Not Applicable / Weighting: 0
two.2.11) Information about options
Options: Yes
Description of options
Following the initial 5 year contract period, the Commissioners has the the option to extend for up to an additional 4 year(s).
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.1) Previous publication concerning this procedure
Notice number: 2025/S 000-054675
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 4
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
University College London Hospitals NHS Foundation Trust
London
NW1 2PG
Country
United Kingdom
NUTS code
- UKI - London
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 4
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Guy's and St Thomas' NHS Foundation Trust
London
SE1 9RT
Country
United Kingdom
NUTS code
- UKI - London
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 4
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Barts Health NHS Trust
London
E1 2ES
Country
United Kingdom
NUTS code
- UKI - London
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 4
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
The Royal Marsden NHS Foundation Trust
London
SW3 6JJ
Country
United Kingdom
NUTS code
- UKI - London
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 1
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Cambridge University Hospitals NHS Foundation Trust
Cambridge
CB2 0QQ
Country
United Kingdom
NUTS code
- UKH - East of England
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 2
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
Oxford University Hospitals NHS FT
Oxford
OX3 9DU
Country
United Kingdom
NUTS code
- UKJ - South East (England)
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 2
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
University Hospitals Southampton
Southampton
SO16 6YD
Country
United Kingdom
NUTS code
- UKJ - South East (England)
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 2
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol
BS1 3NU
Country
United Kingdom
NUTS code
- UKK - South West (England)
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 3
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST
Leicester
LE1 5WW
Country
United Kingdom
NUTS code
- UKF - East Midlands (England)
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 2
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne
NE1 4LP
Country
United Kingdom
NUTS code
- UKC - North East (England)
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 2
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
The Christie NHS Foundation Trust
Manchester
M204BX
Country
United Kingdom
NUTS code
- UKD - North West (England)
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section five. Award of contract
A contract/lot is awarded: Yes
five.2) Award of contract
five.2.1) Date of conclusion of the contract
16 December 2025
five.2.2) Information about tenders
Number of tenders received: 2
The contract has been awarded to a group of economic operators: No
five.2.3) Name and address of the contractor
THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST
Wirral
CH634JY
Country
United Kingdom
NUTS code
- UKD - North West (England)
The contractor is an SME
No
five.2.4) Information on value of contract/lot (excluding VAT)
Initial estimated total value of the contract/lot: £11,876,000
Total value of the contract/lot: £11,876,000
Section six. Complementary information
six.3) Additional information
This is a Provider Selection Regime(PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.
The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by Wednesday 28th January 2026. Representations should be sent to jessica.gaucher-thompson@nhs.net. The award decision-makers are NHS England National Commissioning Group (NCG).
These contracts have not yet formally been awarded; this notice serves as an intention to award under the PSR.
The Key Criteria used for the award:
Quality & innovation: 50%
Value: 2%
Integration, Collaboration & Service Sustainability: 21%
Improving Access, Reducing Health Inequalities and Facilitating Choice: 17%
Social Value: 10%.
The rationale for selecting the provider(s) was based on them meeting all mandatory requirements and achieving the minimum quality threshold set out in the procurement documentation. This decision has been made as per NHS England governance processes, by the National Commissioning Group on 16th December 2025. No conflicts of Interest were identified amongst decision-makers.
six.4) Procedures for review
six.4.1) Review body
NHS Arden and Greater East Midlands Commissioning Support Unit
Cardinal Square, 10 Nottingham Road
Derby
DE1 3QT
Country
United Kingdom